Tags

Type your tag names separated by a space and hit enter

Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience.
Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):291-8.IJ

Abstract

PURPOSE

To update the Memorial Sloan-Kettering Cancer Center's experience with intensity-modulated radiotherapy (IMRT) in the treatment of oropharyngeal cancer (OPC).

METHODS AND MATERIALS

Between September 1998 and April 2009, 442 patients with histologically confirmed OPC underwent IMRT at our center. There were 379 men and 63 women with a median age of 57 years (range, 27-91). The disease was Stage I in 2%, Stage II in 4%, Stage III in 21%, and Stage IV in 73% of patients. The primary tumor subsite was tonsil in 50%, base of tongue in 46%, pharyngeal wall in 3%, and soft palate in 2%. The median prescription dose to the planning target volume of the gross tumor was 70 Gy for definitive (n = 412) cases and 66 Gy for postoperative cases (n = 30). A total 404 patients (91%) received chemotherapy, including 389 (88%) who received concurrent chemotherapy, the majority of which was platinum-based.

RESULTS

Median follow-up among surviving patients was 36.8 months (range, 3-135). The 3-year cumulative incidence of local failure, regional failure, and distant metastasis was 5.4%, 5.6%, and 12.5%, respectively. The 3-year OS rate was 84.9%. The incidence of late dysphagia and late xerostomia ≥Grade 2 was 11% and 29%, respectively.

CONCLUSIONS

Our results confirm the feasibility of IMRT in achieving excellent locoregional control and low rates of xerostomia. According to our knowledge, this study is the largest report of patients treated with IMRT for OPC.

Authors+Show Affiliations

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21167652

Citation

Setton, Jeremy, et al. "Intensity-modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: an Update of the Memorial Sloan-Kettering Cancer Center Experience." International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 1, 2012, pp. 291-8.
Setton J, Caria N, Romanyshyn J, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2012;82(1):291-8.
Setton, J., Caria, N., Romanyshyn, J., Koutcher, L., Wolden, S. L., Zelefsky, M. J., Rowan, N., Sherman, E. J., Fury, M. G., Pfister, D. G., Wong, R. J., Shah, J. P., Kraus, D. H., Shi, W., Zhang, Z., Schupak, K. D., Gelblum, D. Y., Rao, S. D., & Lee, N. Y. (2012). Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. International Journal of Radiation Oncology, Biology, Physics, 82(1), 291-8. https://doi.org/10.1016/j.ijrobp.2010.10.041
Setton J, et al. Intensity-modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: an Update of the Memorial Sloan-Kettering Cancer Center Experience. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):291-8. PubMed PMID: 21167652.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. AU - Setton,Jeremy, AU - Caria,Nicola, AU - Romanyshyn,Jonathan, AU - Koutcher,Lawrence, AU - Wolden,Suzanne L, AU - Zelefsky,Michael J, AU - Rowan,Nicholas, AU - Sherman,Eric J, AU - Fury,Matthew G, AU - Pfister,David G, AU - Wong,Richard J, AU - Shah,Jatin P, AU - Kraus,Dennis H, AU - Shi,Weiji, AU - Zhang,Zhigang, AU - Schupak,Karen D, AU - Gelblum,Daphna Y, AU - Rao,Shyam D, AU - Lee,Nancy Y, Y1 - 2010/12/16/ PY - 2010/08/10/received PY - 2010/10/08/revised PY - 2010/10/12/accepted PY - 2010/12/21/entrez PY - 2010/12/21/pubmed PY - 2012/3/20/medline SP - 291 EP - 8 JF - International journal of radiation oncology, biology, physics JO - Int J Radiat Oncol Biol Phys VL - 82 IS - 1 N2 - PURPOSE: To update the Memorial Sloan-Kettering Cancer Center's experience with intensity-modulated radiotherapy (IMRT) in the treatment of oropharyngeal cancer (OPC). METHODS AND MATERIALS: Between September 1998 and April 2009, 442 patients with histologically confirmed OPC underwent IMRT at our center. There were 379 men and 63 women with a median age of 57 years (range, 27-91). The disease was Stage I in 2%, Stage II in 4%, Stage III in 21%, and Stage IV in 73% of patients. The primary tumor subsite was tonsil in 50%, base of tongue in 46%, pharyngeal wall in 3%, and soft palate in 2%. The median prescription dose to the planning target volume of the gross tumor was 70 Gy for definitive (n = 412) cases and 66 Gy for postoperative cases (n = 30). A total 404 patients (91%) received chemotherapy, including 389 (88%) who received concurrent chemotherapy, the majority of which was platinum-based. RESULTS: Median follow-up among surviving patients was 36.8 months (range, 3-135). The 3-year cumulative incidence of local failure, regional failure, and distant metastasis was 5.4%, 5.6%, and 12.5%, respectively. The 3-year OS rate was 84.9%. The incidence of late dysphagia and late xerostomia ≥Grade 2 was 11% and 29%, respectively. CONCLUSIONS: Our results confirm the feasibility of IMRT in achieving excellent locoregional control and low rates of xerostomia. According to our knowledge, this study is the largest report of patients treated with IMRT for OPC. SN - 1879-355X UR - https://www.unboundmedicine.com/medline/citation/21167652/Intensity_modulated_radiotherapy_in_the_treatment_of_oropharyngeal_cancer:_an_update_of_the_Memorial_Sloan_Kettering_Cancer_Center_experience_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(10)03468-1 DB - PRIME DP - Unbound Medicine ER -